Update 2: Fucoidan and novel coronavirus (COVID-19)
As reported in Marinova’s March 2020 update, Marinova has previously investigated the in vitro effects of Maritech® fucoidan on coronaviruses and noted little activity in comparison to the extent observed with other viruses such as influenza, herpes, human metapneumovirus and respiratory syncytial virus. Marinova is now screening the in vitro activity of Maritech® fucoidan with regard to the novel coronavirus (COVID-19).
In recent weeks, Marinova has been liaising with leading research institutions and national authorities in regard to testing Maritech® fucoidan against COVID-19. The work being undertaken in this area aligns with ongoing research being conducted by Marinova examining the effects of Maritech® fucoidan on respiratory illness.
Marinova continues its active research program into the immune-modulatory properties of fucoidan. An extensive body of evidence supports the understanding that fucoidan exerts a range of beneficial effects on the human immune system. This includes boosting the immune response, activating Natural Killer cells and cytotoxic T cells, the mobilization of stem cells and the dampening of allergic responses. A summary of the evidence for Maritech® fucoidan as an immune support agent can be found here.